[
  {
    "ts": null,
    "headline": "Altria Among 6 Dividend Kings To Announce Annual Payout Increases In August",
    "summary": "We saw 10%+ increases from several companies. Read here for expert predictions on upcoming dividend increases from top companies with long-term growth.",
    "url": "https://finnhub.io/api/news?id=d2ae9bd6e5454c756582c500989e47dcbf4719d76472c57e16c6a29a35d4b77d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753990826,
      "headline": "Altria Among 6 Dividend Kings To Announce Annual Payout Increases In August",
      "id": 136158983,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458110161/image_458110161.jpg?io=getty-c-w1536",
      "related": "WST",
      "source": "SeekingAlpha",
      "summary": "We saw 10%+ increases from several companies. Read here for expert predictions on upcoming dividend increases from top companies with long-term growth.",
      "url": "https://finnhub.io/api/news?id=d2ae9bd6e5454c756582c500989e47dcbf4719d76472c57e16c6a29a35d4b77d"
    }
  },
  {
    "ts": null,
    "headline": "GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised",
    "summary": "Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.",
    "url": "https://finnhub.io/api/news?id=5aafb9dfc09b09f694801d1ae116ed61155eec2ed34f643447b1c4d9fa3b065a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753982820,
      "headline": "GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised",
      "id": 136161077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.",
      "url": "https://finnhub.io/api/news?id=5aafb9dfc09b09f694801d1ae116ed61155eec2ed34f643447b1c4d9fa3b065a"
    }
  },
  {
    "ts": null,
    "headline": "CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised",
    "summary": "CNMD reports solid second-quarter results, driven by improving sales across both segments.",
    "url": "https://finnhub.io/api/news?id=c4f7b7e8d31fd5063f9de7eb6208c282b795e9da8e80f352d1df2944a5478ffc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753982700,
      "headline": "CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised",
      "id": 136161078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "CNMD reports solid second-quarter results, driven by improving sales across both segments.",
      "url": "https://finnhub.io/api/news?id=c4f7b7e8d31fd5063f9de7eb6208c282b795e9da8e80f352d1df2944a5478ffc"
    }
  },
  {
    "ts": null,
    "headline": "Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands",
    "summary": "MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.",
    "url": "https://finnhub.io/api/news?id=ddf163cf097a97a734f5f88e7b0b718fd303cb3375566cba92f5e27b06e9a36b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753982280,
      "headline": "Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands",
      "id": 136161079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.",
      "url": "https://finnhub.io/api/news?id=ddf163cf097a97a734f5f88e7b0b718fd303cb3375566cba92f5e27b06e9a36b"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call",
    "summary": "West Pharmaceutical Services delivered a quarter that outperformed Wall Street’s expectations, reflecting renewed strength in its core high-value product (HVP) components. Management attributed the results primarily to robust demand for GLP-1 elastomer products, ongoing conversions to HVP driven by regulatory upgrades, and the normalization of customer ordering patterns. CEO Eric Green highlighted that the company’s proprietary products segment saw particularly solid growth, with HVP components",
    "url": "https://finnhub.io/api/news?id=b0daa7e8d8201764c63ca22699da15d093455261ade05a8c962b75f920b8b057",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753939988,
      "headline": "The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call",
      "id": 136149862,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services delivered a quarter that outperformed Wall Street’s expectations, reflecting renewed strength in its core high-value product (HVP) components. Management attributed the results primarily to robust demand for GLP-1 elastomer products, ongoing conversions to HVP driven by regulatory upgrades, and the normalization of customer ordering patterns. CEO Eric Green highlighted that the company’s proprietary products segment saw particularly solid growth, with HVP components",
      "url": "https://finnhub.io/api/news?id=b0daa7e8d8201764c63ca22699da15d093455261ade05a8c962b75f920b8b057"
    }
  }
]